The hyperbole was the 50 year test requirement. Animal trials would have been nice. Children, mothers, old were not in the clinical phase 1/2; Your reasons are flawed.
“Children, mothers, old were not in the clinical phase 1/2; Your reasons are flawed.”
Hmmm.... what about phse 3?
“A review of unblinded reactogenicity data from the final analysis which consisted of a randomized subset of at least 8,000 participants 18 years and older in the phase 2/3 study demonstrates that the vaccine was well tolerated, with most solicited adverse events resolving shortly after vaccination.....
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.”
Children were not looked at and the initial release didn’t authorize them. Mothers and the old were looked at, with the elderly overrepresented in samples, both in phase 2 and phase 3.